
Billiontoone Inc (BLLN) Stock Forecast & Price Target
Billiontoone Inc (BLLN) Analyst Ratings
Bulls say
BillionToOne is compelling because its Q3 showed durable fundamental momentum, with revenue of $123M rising 47% Y/Y, a 6% top-line beat, 71% gross margin, and $23M of adjusted EBITDA, while cash remained strong at $562M. Its bullish case is reinforced by reimbursement de-risking and commercial scale, as payor coverage now totals about 300M lives, Q3 oncology revenue grew 96% Y/Y, and the company raised its 2026 revenue guide to $460M-$470M. In addition, the validation of Northstar Response against a market-leading MRD assay, the planned December 15, 2026 launch of Northstar Clear, and continued expansion in UNITY and oncology support a long runway for share gains and operating leverage.
Bears say
BillionToOne is facing a difficult fundamental setup because it operates in highly competitive prenatal and oncology diagnostics markets while relying on proprietary QCT technology that may be harder to defend amid litigation risk and intense rivals like Natera, Guardant Health, LabCorp, and Quest. Its business is also heavily exposed to reimbursement and billing execution, so delays in claims or failures to secure Medicare and Medicaid payment could directly pressure revenue from molecular tests that drive essentially all of its growth. Although 2026 revenue is modeled at $456M and 2028 at $780M, rising operating expenses of $293M and $438M, along with softer ASPs and margin pressure after Q2'26 gross margin fell to 70%, suggest scaling remains costly and execution-sensitive.
This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.
Billiontoone Inc (BLLN) Analyst Forecast & Price Prediction
Start investing in Billiontoone Inc (BLLN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Billiontoone Inc (BLLN) Forecast
Billiontoone Inc (BLLN) Analyst Forecast & Price Prediction
Start investing in Billiontoone Inc (BLLN)
Order type
Buy in
Order amount
Est. shares
0 shares